Bank of New York Mellon’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q3 | – | Sell |
-635,396
| Closed | -$9.52M | – | 4368 |
|
|
2016
Q2 | $9.52M | Sell |
635,396
-76,544
| -11% | -$983K | ﹤0.01% | 1876 |
|
|
2016
Q1 | $8.66M | Buy |
711,940
+445,247
| +167% | +$6.24M | ﹤0.01% | 1913 |
|
|
2015
Q4 | $4.24M | Buy |
266,693
+19,657
| +8% | +$309K | ﹤0.01% | 2317 |
|
|
2015
Q3 | $3.79M | Buy |
247,036
+29,175
| +13% | +$631K | ﹤0.01% | 2396 |
|
|
2015
Q2 | $5.3M | Buy |
217,861
+8,716
| +4% | +$209K | ﹤0.01% | 2320 |
|
|
2015
Q1 | $4.86M | Buy |
209,145
+6,628
| +3% | +$175K | ﹤0.01% | 2329 |
|
|
2014
Q4 | $5.08M | Sell |
202,517
-35,414
| -15% | -$1.04M | ﹤0.01% | 2304 |
|
|
2014
Q3 | $7.4M | Sell |
237,931
-4,643
| -2% | -$126K | ﹤0.01% | 2080 |
|
|
2014
Q2 | $6.27M | Buy |
242,574
+98,243
| +68% | +$2.18M | ﹤0.01% | 2195 |
|
|
2014
Q1 | $3.37M | Buy |
144,331
+6,869
| +5% | +$150K | ﹤0.01% | 2546 |
|
|
2013
Q4 | $3.49M | Buy |
137,462
+34,889
| +34% | +$788K | ﹤0.01% | 2524 |
|
|
2013
Q3 | $2.09M | Buy |
102,573
+2,368
| +2% | +$52.7K | ﹤0.01% | 2821 |
|
|
2013
Q2 | $2.1M | Buy |
+100,205
| New | +$1.79M | ﹤0.01% | 2756 |
|
Bank of New York Mellon's SGNT Position: Q3 2016 in Review
Bank of New York Mellon sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q3 2016, closing a stake of 635,396 shares — an estimated $9.52M sold.
Bank of New York Mellon first reported a position in SGNT in Q2 2013 and held it in 13 quarters. The position peaked at $9.52M in Q2 2016. 0 funds tracked by Wall St. Rank hold SGNT as of Q3 2016.
- Bank of New York Mellon reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q3 2016 after selling out during the quarter.
- Bank of New York Mellon sold 635,396 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q3 2016, an estimated $9.52M.
- Bank of New York Mellon first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2013 and held it in 13 quarters.
- Bank of New York Mellon's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $9.52M in Q2 2016.
- 0 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q3 2016.
Based on Bank of New York Mellon's 13F filing for Q3 2016, filed 3 Nov 2016.